El interés en corto de Gaxos.AI da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Gaxos.AI. Los datos de interés en corto se actualizan cada dos semanas.

Gaxos.AI (NASDAQ:GXAI) Bolsa, Informe de interés en corto

Gaxos.AI

Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.

Gaxos.AI Inc

D. Boral Capital analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENLV#NASDAQ">ENLV</a>) with a Buy and maintains $13 price target.

News

Price Target

Analyst Ratings

ENLV

D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target

Kidpik (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIK#NASDAQ">PIK</a>) reported quarterly losses of $(0.45) per share. This is a 62.5 percent increase over losses of $(1.20) per share from the same period last year. The company reported $1.00 million in sales this quarter. This is a 70.49 percent decrease over sales of $3.39 million the same period last year.

Earnings

Kidpik Q3 EPS $(0.45) Up From $(1.20) YoY, Sales $1.00M Down From $3.39M YoY

TMC Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate.

TMC Metals Q3 2024 GAAP EPS $(0.06), Inline

HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) reported $426.42 thousand in sales this quarter. This is a 50.02 percent decrease over sales of $853.10 thousand the same period last year.

HCWB

HCW Biologics Q3 Sales $426.42K Down From $853.10K YoY

AGFY

Agrify Q3 EPS $(17.31) Up From $(19.02) YoY; Revenue $1.934M Down From $3.139M YoY

Trading Ideas

BRK/A

POOL

SIRI

Berkshire Hathaway 13F Shows Added New Stake In Sirius XM Holdings With 105.16M Shares, Worth $2.49B; Added New Stake In Domino's Pizza With 1.28M Shares, Worth $549.4M; Added New Stake In Pool Corp With 404,057 Shares, Worth $152.2M

Berkshire Hathaway 13F Shows Increased Stake In American Express By 17% To 151.6M Shares, Now Worth $41.1B; Increased Stake In Kroger By 15% To 50M Shares, Worth $2.87B; Increased Stake In DaVita By 18%, Now Valued At $5.92B; Increased Stake In Moody's Corp By 13% To 24.67M Shares, Now Worth $11.71B

ROLR

High Roller Technologies Unaudited Q3 Revenue $7.52M Up From $5.80M QoQ

Telsey Advisory Group analyst Dana Telsey maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Outperform and maintains $8 price target.

EWCZ

Telsey Advisory Group Maintains Outperform on European Wax Center, Maintains $8 Price Target

CHTR

Berkshire Hathaway 13F Shows Reduced Stake In Bank Of America By 23% To 797.7M Shares, Worth $31.7B; Reduced Stake In Charter Communications By 26% To 2.82M Shares, Worth $914.5M; Reduced Stake In Nu Holdings By 19% To 86.4M Shares, Worth $1.18B; Reduced Stake In Occidental Petroleum By 18%, Now Valued At $13.16B

Consolidated Water Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWCO#NASDAQ">CWCO</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.25 by 24 percent. The company reported quarterly sales of $33.391 million which beat the analyst consensus estimate of $31.750 million by 5.17 percent. This is a 33.02 percent decrease over sales of $49.854 million the same period last year.

Earnings Beats

CWCO

Consolidated Water Co Q3 2024 GAAP EPS $0.31 Beats $0.25 Estimate, Sales $33.391M Beat $31.750M Estimate

NMHI

Nature's Miracle Holding Q3 EPS $(0.09), Sales $3.05M Up From $2.69M YoY

D. Boral Capital analyst Jason Kolbert maintains Kairos Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KAPA#AMEX">KAPA</a>) with a Buy and maintains $9 price target.

KAPA

D. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target

<a href="https://truthsocial.com/@realDonaldTrump/113483513301208163" title="https://truthsocial.com/@realDonaldTrump/113483513301208163">https://truthsocial.com/@realDonaldTrump/113483513301208163</a>

Macro Notification

Politics

General

CORRECTION: Trump Picks Jay Clayton For U.S. Attorney For The Southern District Of New York

Astera Labs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) shares are up 23.4% to $89.54 in November following the company's <a href="https://www.benzinga.com/news/earnings/24/11/41754359/astera-labs-stock-is-ripping-higher-today-whats-going-on">impressive third-quarter earnings</a> beat Wall Street expectations, reinforcing its role as a critical player in AI infrastructure. 
What To Know: Astera reported earnings of 23 cents per share, exceeding the estimated 17 cents, alongside revenue of $113.1 million, up 206% year-over-year and well above analyst forecasts of $97.4 million. 
CEO Jitendra Mohan highlighted that the company achieved its fifth consecutive quarter of record-breaking revenue, with sales rising 47% from the previous quarter, driven by new growth in AI connectivity solutions.
Astera's latest product, the Scorpio Smart Fabric Switch, is central to its strategy. These switches are designed to enhance data transfer speeds between GPUs, CPUs and storage devices, addressing critical needs in AI data centers where performance demands are skyrocketing.
Read Also: <a href="https://www.benzinga.com/tech/24/11/41973572/ray-dalios-bridgewater-cuts-stake-in-microsoft-stock-by-20-is-big-tech-losing-its-shine">Ray Dalio&#8217;s Bridgewater Cuts Stake In Microsoft Stock By 20% – Is Big Tech Losing Its Shine?</a>
What Else: The company's strong performance and promising product pipeline prompted multiple analysts to raise their price targets.
JPMorgan increased its target to $110 per share, while Deutsche Bank, Barclays and others <a href="https://www.benzinga.com/quote/ALAB/analyst-ratings">made upward revisions</a>. 
Astera's revenue forecast for the fourth quarter of $126–$130 million, alongside expected earnings of 25 cents to 26 cents per share, has added momentum to investor enthusiasm.
Read Also: <a href="https://www.benzinga.com/24/11/41971559/disneys-q4-boosted-by-streaming-gains-strong-box-office-and-solid-parks-performance">Disney Q4 Earnings: Revenue And Profit Beat, Best Film Studio Performance, 3-Year Outlook And More</a>
<h2 class="wp-block-heading">How To Buy ALAB Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Astera Labs&#8217; case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ALAB has a 52-week high of $100.09 and a 52-week low of $36.22.

ALAB

Astera Labs (ALAB) Stock Is Up 23% This Month: What's Going On?

CV Sciences, Inc. (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTCQB">CVSI</a>), a <a href="http://benzinga.com/topic/hemp">hemp</a>-focused wellness company, announced stable revenue in its Q3 2024 financials on Thursday. The company generated $3.9 million in revenue, a slight decline from $4.1 million in Q3 2023, yet maintained a gross margin of 46%, up from 45.1% the previous year.
<h4 class="wp-block-heading">Q3 2024 Financial Highlights</h4>
<ul>
<li>Revenue: $3.9 million, a 5% decline from $4.1 million in Q3 2023 and stable compared to <a href="https://www.benzinga.com/markets/cannabis/24/08/40344002/hemp-focused-cv-sciences-reports-flat-revenue-and-over-8-yoy-increase-in-gross-profit-in-q2">$4 million in Q2 2024</a>.</li>
<li>Net loss: $456,000, slightly higher than the $447,000 loss in Q3 2023.</li>
<li>Adjusted EBITDA: Loss of $75,000, significantly improved from a loss of $361,000 in Q3 2023.</li>
<li>Gross profit: $1.78 million, a slight decrease from $1.84 million in Q3 2023, reflecting an improved gross margin of 46%, up from 45.1% in the same period last year.</li>
</ul>
<h3 class="wp-block-heading">New Product Lines Boost Growth</h3>
Operating with a cash balance of $1 million, CV Sciences recorded an adjusted EBITDA loss of $75,000, <a href="https://www.benzinga.com/markets/cannabis/24/03/37988133/hemp-focused-wellness-co-moves-closer-to-profitability-reports-flat-2023-revenue-increase-in-gro">inching closer</a> to cash flow break-even.
Furthermore, the company's recent launches, including the cannabinoid-free +PlusHLTH supplement line, target cognitive health, stress relief and metabolism support. Additionally, CV Sciences expanded its pet health segment with hip, joint and calming chews, aiming to capture a broader consumer base.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Management Commentary</h3>
CEO Joseph Dowling highlighted the <a href="https://www.benzinga.com/markets/cannabis/24/08/40344002/hemp-focused-cv-sciences-reports-flat-revenue-and-over-8-yoy-increase-in-gross-profit-in-q2">steady core revenue</a> in a challenging environment, noting new products and acquisitions as positioning factors for growth in 2025. &#8220;Our third quarter 2024 progress demonstrates our continuous commitment to innovation and cost-efficient execution as we move closer to profitability and positive cash flow,&#8221; Dowling <a href="https://www.prnewswire.com/news-releases/cv-sciences-inc-reports-third-quarter-2024-financial-results-302305079.html">said</a> in a press release.
Read Also: <a href="https://www.benzinga.com/24/11/41971875/cbd-pioneer-charlottes-web-narrows-loss-in-q3-focuses-on-long-term-growth-amid-challenging-cannabis-industry-environment">CBD Pioneer Charlotte&#8217;s Web Narrows Loss In Q3, Focuses On Long-Term Growth</a>
"We look forward to organically grow our business and pursue additional M&amp;A opportunities in the near future to improve our top-line revenue, profitability and shareholder value," he added.
<h3 class="wp-block-heading">CV Sciences Holds Top Market Spot</h3>
In Q3, CV Sciences further solidified its market position, maintaining top-seller status in the natural products retail channel, according to SPINS data. The company also secured $0.9 million in financing from Streeterville, aimed at fueling operational and product expansion.
CVSI Price Action CVSI's shares were trading 7.73% lower at $0.04235 per share at the time of this writing around 12:35 PM ET Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41974843/cbd-pharma-co-medipharm-37-increase-in-q3-international-sales-15-yoy-revenue-growth">CBD Pharma Co. MediPharm: 37% Increase In Q3 International Sales, 15% YoY Revenue Growth</a></li>
</ul>

Cannabis

CVSI

CV Sciences Q3: Revenue Stable Amid New Launches, Financing

RIVN

iShares Trust Barclays 20+ Year Treasury Bond Fund

Soros Fund Management 13F Shows Exited Position In SPDR S&P 500 ETF, Previously Holding 450,000 Shares; Exited Stake In Rivian Automotive Call Options, Previously Holding 5,450,000 Shares; Exited Put Position In Ishares 20+ Year Treasury Bond ETF, Previously Holding 360,000 Shares; Exited Stake In Westrock Co, Previously Holding 3,342,953 Shares;  Exited Stake In Livongo Health Convertible Notes, Previously Holding $45M In Principal

PMNT

Perfect Moment Q2 EPS $(0.17) Up From $(0.29) YoY; Revenue $3.833M Down From $5.888M YoY

Canaccord Genuity analyst Joseph Vafi maintains Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) with a Buy and raises the price target from $22 to $32.

Canaccord Genuity Maintains Buy on Hut 8, Raises Price Target to $32

PXLW

Pixelworks Enters $10M "At-The-Market" Equity Offering Agreement With Roth Capital, Allowing Periodic Common Stock Sales With 2.5% Commission; Roth To Act As Sales Agent

Gaxos.ai files to sell 1.93M common shares for holders

FNGR, IHRT among major communication services gainers; DRCT, PERI among losers

KUKE, MNY among major communication services gainers; CCG, DJT among losers

PARA, GCI among major communication services gainers; DASH, MDIA among losers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Gaxos.AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/gxai-stock-quote/">GXAI</a>) just reported results for the first quarter of 2024.<ul><li>Gaxos.AI reported earnings per share of -91 cents.</li><li>The company reported revenue of $19.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/gxai-stock-earnings-gaxos-ai-for-q1-of-2024/">GXAI Stock Earnings: Gaxos.AI Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GXAI Stock Earnings: Gaxos.AI Reported Results for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Gaxos.AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/gxai-stock-quote/">GXAI</a>) just reported results for the fourth quarter of 2023.<ul><li>Gaxos.AI reported earnings per share of -76 cents.</li><li>The company reported revenue of $256.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/gxai-stock-earnings-gaxos-ai-for-q4-of-2023/">GXAI Stock Earnings: Gaxos.AI Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GXAI Stock Earnings: Gaxos.AI Reported Results for Q4 2023

Gaxos Health announces partnerships with leading testing laboratories

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Gaxos.AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/gxai-stock-quote/">GXAI</a>) just reported results for the second quarter of 2024.<ul><li>Gaxos.AI reported earnings per share of -72 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/gxai-stock-earnings-gaxos-ai-for-q2-of-2024/">GXAI Stock Earnings: Gaxos.AI Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

GXAI Stock Earnings: Gaxos.AI Reported Results for Q2 2024

06:32 EDT Gaxos.AI (GXAI) files to sell 2.61M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, mar...

Gaxos.AI files to sell 2.61M shares of common stock for holders

Gaxos.ai (GXAI) announced that the Company's Board of Directors approved the purchase of up to $1 million in Bitcoin. "As demand for Bitcoin grows ...

Gaxos.AI board of directors approves Bitcoin as treasury reserve asset

ABLV

ANGI

BHAT

BILI

CURI

DASH

DRCT

FNGR

GAME

GXAI

IHRT

KUKE

MDIA

PARA

PERI

PODC

BestGrowthStocks.Com Issues Comprehensive Analysis of Gaxos.Ai Inc.

Press Releases

Gaxos Health Announces Strategic Partnerships with Leading Testing Laboratories

Gaxos Health Announces Commercial Launch

Gaxos to Participate in Upcoming Devcom and Gamescom Conferences on August 18th to 25th in Cologne, Germany

Gaxos to Participate in Unity's Upcoming Unite 2024 Conference on September 18th to 20th in Barcelona, Spain

Gaxos.ai Inc. Announces Exercise of Warrants for $3.24 Million Gross Proceeds

Gaxos.AI Launches Gaxos Labs, Offering Game Developers and Publishers New Artificial Intelligence Superpowers

Gaxos to Participate in the Game Industry Conference on October 24th to October 27th in Poznan, Poland

Gaxos to Participate in The AI Summit New York on December 11th to December 12th in New York City

Gaxos Board of Directors Approves Bitcoin as Treasury Reserve Asset

Blue Hat Interactive Entertainment Technology - Ordinary Shares

Blue Hat Interactive

DoubleDown Interactive Co., Ltd. - American Depository Shares

DoubleDown Interactive

DouYu International Holdings Limited - American Depositary Shares

DouYu Intl Hldgs

Electronic Arts

GDEV

Golden Matrix Group

GRAVITY Co., Ltd. - American depositary shares, each representing one common share.

GRAVITY Co

HUYA Inc. American depositary shares, each representing one Class A ordinary share

HUYA

iHuman Inc. American depositary shares, each representing five Class A ordinary shares

iHuman

Motorsport Games Inc. - Class A Common Stock

Motorsport Games

PLAYSTUDIOS

NetEase, Inc. - American Depositary Shares, each representing 5 ordinary shares

NetEase

Playtika Holding

Roblox

Sea Limited American Depositary Shares, each representing one Class A Ordinary Share

Skillz

Snail

Sohu.com Limited - American Depositary Shares

Sohu.com

TruGolf Holdings, Inc. - Class A Common Stock

TruGolf Holdings

Take-Two Interactive Software, Inc. - Common Stock

Comments

Gaxos.AI

Interés en corto

Gaxos.AI (NASDAQ:GXAI) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL